ALK-Abelló — AGM Information 2017

Feb 14, 2017

Copenhagen, 2017-02-14 14:15 CET (GLOBE NEWSWIRE) --

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The annual general meeting of
ALK-Abelló A/S will take place on Wednesday 15 March 2017 at 16:00 (CET) at
ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting
including the complete proposals from the Board of Directors to the AGM is
attached.

                             ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is a world leader in allergy
immunotherapy – a treatment of the underlying cause of allergy. The company has
approximately 2,300 employees, with subsidiaries, production facilities and
distributors worldwide. ALK has entered into partnership agreements with Torii,
Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets
in Japan, Russia, South-East Asia, Australia and New Zealand, respectively.
The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq
Copenhagen. Find more information at www.alk.net